Home / Market News / $CVS
fiscal.ai Corporate Catalyst Impact 65/100 ● negative

CVS Health to Terminate SilverScript Choice PDP in 13 Regions for 2027

Oct 28, 2026, 9:33 PM UTC · Primary ticker $CVS

CVS Health is terminating its SilverScript Choice stand-alone prescription drug plan in 13 regions for 2027, affecting approximately 950,000 enrollees. This move, representing 81% of total terminated PDP enrollees, will force beneficiaries to seek new coverage and reflects broader market adjustments in private Medicare plans.

CVS Health is discontinuing its SilverScript Choice PDP in 13 regions, impacting nearly a million Medicare Part D beneficiaries. This decision is a strategic portfolio adjustment by CVS, likely aimed at optimizing its Medicare offerings and profitability, potentially by focusing on more integrated or higher-margin plans. While it directly affects a large number of enrollees who must now find new coverage, the financial impact on CVS is likely manageable as it represents a shift rather than a complete withdrawal from the Medicare market. For competitors like Humana, UnitedHealth, and Elevance Health, this could present an opportunity to gain market share as affected beneficiaries seek new plans, though the overall market dynamics remain competitive. Short-term, CVS may incur some administrative costs related to the termination, but long-term, it aims for a more efficient and profitable Medicare presence. Traders should watch for any commentary from CVS on the rationale and expected financial implications, and for competitor responses to the influx of potential new customers.

$CVS neutral Strategic portfolio adjustment
$HUM neutral Competitor in Medicare Part D
$UNH neutral Competitor in Medicare Part D
$ELV neutral Competitor in Medicare Part D
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.